Overview of the Nontyphoidal and Paratyphoidal Salmonella Vaccine Pipeline: Current Status and Future Prospects

Clin Infect Dis. 2020 Jul 29;71(Suppl 2):S151-S154. doi: 10.1093/cid/ciaa514.

Abstract

Nontyphoidal Salmonella and Salmonella Paratyphi are responsible for significant morbidity and mortality worldwide. To date, no vaccine has been licensed against these organisms. The development of effective vaccines remains an urgent priority. In this review, the rationale for and current status of various vaccine candidates against S. Paratyphi and nontyphoidal Salmonella are presented, with a focus on the research findings from the 2019 International Conference on Typhoid and Other Invasive Salmonelloses. Additionally, other vaccine candidates that are currently undergoing clinical development are highlighted. Future approaches, which may include antigens that are genetically conserved across Salmonella and confer broad, non-serotype-specific protection, are also discussed.

Keywords: Salmonella; NTS; Paratyphi; vaccines.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Humans
  • Salmonella Infections* / epidemiology
  • Salmonella Infections* / prevention & control
  • Salmonella Vaccines*
  • Salmonella paratyphi A
  • Typhoid Fever*
  • Typhoid-Paratyphoid Vaccines*

Substances

  • Salmonella Vaccines
  • Typhoid-Paratyphoid Vaccines